Patent Opposition Database: Drugs: Tezacaftor (NA)

Abbreviation: NA
Disease(s): Cystic Fibrosis
Background: .pdf
Patent oppositions filed in: India

Tezacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) corrector used in the treatment of Cystic Fibrosis (CF). It is used in combination with Ivacaftor as Symdeko and in a triple combination regime along with drugs Elexacaftor and Ivcaftor as Trikafta for management of CF.

This drug is missing the following documents, can you help us by contributing something?

Oppositions

Information related to relevant oppositions from around the world.

Patent Oppositions

The table includes oppositions aimed at contesting patents covering this drug. Note that at the country level, several patent applications can cover the same drug.

Please pay attention not only to the patent opposition, but also to the patent application it relates to, see column "Related Patent Application". To better identify similarities, the column "Patent Type" indicates a general classification of the patent. Arguments used to contest a specific type of patent may apply for another that fits in the same category.

Country	Date	Who Filed	Opposition type	Opposition status	Patent type	Related patent application	More info
India	25-03-2021	Dr.Charanjith Kumar Sehgal	Pre-Grant	Opponent did not attend the hearing, the application is rejected	Compositions	3140/KOLNP/2012	View/Comment

Is something missing? Help us by contributing missing data: Contribute

↑ Back to Top

Patent Office Decisions

This table showcases the final ruling of patent offices over cases where patents have been opposed.

To better identify the case, the number of the patent application is provided in the table below.

Decision type	Country	Date	Patent office	Related patent application	More info
Rejection	India	12-12-2022	Indian Patent Office	3140/KOLNP/2012	View/Comment